Opendata, web and dolomites

SECRET SIGNED

Exploitation of the SECRETory pathway for cancer therapy to address European research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SECRET project word cloud

Explore the words cloud of the SECRET project. It provides you a very rough idea of what is the project "SECRET" about.

contributes    academia    applicable    evasion    therapy    proteins    therapeutic    holds    accounting    death    regulation    signaling    activation    bc    selective    serve    coordinated    career    polarity    inspire    progression    metastasis    interrogate    frequent    colorectal    talented    treatment    biology    poor    university    chemotherapy    purposes    negative    trove    strategies    subgroup    option    secretion    incomplete    cell    esrs    19    15    metastases    intersectoral    aberrant    countries    tumor    interdisciplinary    prone    regulated    patients    cancers    triple    deaths    secretome    translational    dysregulated    stuttgart    altered    rates    underpinning    secret    approved    therapies    train    driver    training    invasion    treasure    crc    presentation    industry    microenvironment    suppression    secretory    promise    motility    platform    tnbc    mutual    breast    beneficiaries    medicine    hyperproliferation    resistance    shaping    infancy    broadly    drive    prognosis    hallmarks    diagnostic    limited    11    cancer   

Project "SECRET" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET STUTTGART 

Organization address
address: KEPLERSTRASSE 7
city: STUTTGART
postcode: 70174
website: www.uni-stuttgart.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙955˙339 €
 EC max contribution 3˙955˙339 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET STUTTGART DE (STUTTGART) coordinator 758˙365.00
2    UNIVERSITETET I OSLO NO (OSLO) participant 584˙684.00
3    STICHTING VUMC NL (AMSTERDAM) participant 531˙239.00
4    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 292˙342.00
5    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 264˙207.00
6    TEL AVIV UNIVERSITY IL (TEL AVIV) participant 263˙500.00
7    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 261˙499.00
8    CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH DE (FREIBURG) participant 252˙788.00
9    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 252˙788.00
10    ANAXOMICS BIOTECH SL ES (BARCELONA) participant 250˙904.00
11    PROTATOUANS - ETAIREIA EREYNAS VIOTECHNOLOGIAS MONOPROSOPI ETAIREIA PERIORISMENIS EYTHINIS EL (GLYFADA) participant 243˙017.00

Map

 Project objective

Breast and colorectal cancer (BC and CRC) are the most frequent cancers accounting for 19% of all deaths from cancer in Europe. In case of triple-negative BC (TNBC) targeted therapies are not available and non-selective chemotherapy is the only treatment option. Targeted therapy has been approved for the treatment of advanced CRC, but response rates are low and treatment is limited to a subgroup of patients. Also, TNBC and CRC patients are prone to develop metastases and have a poor prognosis underpinning the need for new targeted and broadly applicable therapeutic strategies. Tumor cell secretion contributes to hallmarks of cancer e.g. hyperproliferation, evasion of growth suppression, loss of cell polarity, activation of cell motility, invasion and metastasis, shaping of the tumor microenvironment through altered presentation of proteins and the secretome, and resistance to cell death. Dysregulated secretion is thus a driver of cancer progression and therefore holds promise as a general therapeutic target for the treatment of cancers. However, strategies to exploit the secretory pathway for therapeutic and diagnostic purposes are still in their infancy due to the incomplete understanding of how this pathway is regulated by aberrant signaling. The overall research objective of SECRET is to drive the understanding of the mutual regulation of the secretory pathway and signaling in cancer, which will serve as a platform to identify and interrogate novel diagnostic and therapeutic strategies. SECRET comprises 11 beneficiaries and 7 partner organizations from 9 countries. Coordinated by the University of Stuttgart, SECRET will train 15 talented ESRs in the field of translational cancer systems cell biology and systems medicine towards a career in industry or academia through a highly interdisciplinary and intersectoral research training programme and inspire them to exploit the SECRETory pathway as a treasure trove to design novel therapeutic strategies against cancer.

 Publications

year authors and title journal last update
List of publications.
2019 Olayioye, Noll, Hausser
Spatiotemporal Control of Intracellular Membrane Trafficking by Rho GTPases
published pages: 1478, ISSN: 2073-4409, DOI: 10.3390/cells8121478
Cells 8/12 2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SECRET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SECRET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More  

DELIVER (2019)

DELIVERy of advanced therapies for diabetes training network

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More